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Introduction: The microRNA-200 (miR-200) family is known to 
have a pivotal role in regulating epithelial to mesenchymal transition 
through the suppression of transcription factors of E-Cadherin, 
ZEB1, and ZEB2, but the role of miR-200 family in the migration 
and invasion of breast cancer cells is controversial. The lysyl 
oxidase-like 4 (LOXL4), a member of the lysyl oxidase (LOX) 
family, is involved in extracellular matrix (ECM) modulation and 
signaling pathway related to cancer cell growth and survival. 
 iv 
However, the role of LOXL4 in breast cancer progression and 
metastasis is still unclarified. This study investigated the 
mechanisms by which the miR-200 family modulated the migratory 
and invasive abilities of aggressive triple-negative breast cancer 
(TNBC) cells, which have the worst prognosis among breast cancer 
subtypes. In addition, the role of LOXL4 in tumor formation and 
metastasis in TNBC was investigated and overall survival (OS) was 
analyzed to evaluate its clinical significance as a prognostic factor in 
TNBC patients. 
Methods: The miR-200 family (miR-200b/200a/429 and miR-
141/200c clusters) coupled with green fluorescence protein (GFP), 
the LOXL4 shRNA (shLOXL4) coupled with red fluorescence 
protein (RFP) and the firefly luciferase (Luc) coupled with GFP 
were transduced into MDA-MB-231 cells, TNBC cells, using a 
lentiviral system. Gene expression was evaluated using real-time 
polymerase chain reaction (PCR) or reverse transcriptase-PCR 
(RT-PCR). The migratory and invasive abilities were assessed 
using trans-well or wound-healing assays. The secreted cytokines 
and growth factors from cells were quantified using a Bio-Plex 200 
multiplex array system. Western blot and immunofluorescence 
 v 
staining were conducted to investigate the signaling pathways. The 
xenograft tumor models were produced by injection with breast 
cancer cells into the mammary gland or tail vein of 6-week old 
female Balb/c nude mice for an orthotopic or lung metastatic model, 
respectively. Primary tumor volumes were measured by a digital 
caliper. The primary tumor in mammary gland and metastatic lung 
burden were obtained using IVIS and Maestro imaging system. 
Histological analysis was assessed by H&E, Picrosirius red, 
Masson’s trichrome and immunostaining. Second harmonic 
generation (SHG) imaging was conducted to quantify the collagen 
fiber lengths, straightness, and widths. A public database 
(BreastMark) for overall survival (OS) was used to examine the 
prognostic value of the LOXL4, collagen I, and collagen IV genes in 
breast cancer patients. 
Results: The overexpression of the miR-200b/200a/429 or miR-
141/200c cluster suppressed cell growth, but significantly 
increased migration and invasion of MDA-MB-231 cells, and led to 
an increase in the phosphorylation of focal adhesion kinase (FAK) 
and protein kinase B (AKT). Chemical inhibitors of FAK and 
 vi 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT 
suppressed the migration and invasion of MDA-MB-231 cells 
which was enhanced by the overexpression of the miR-
200b/200a/429 or miR-141/200c cluster. Compared to the miR-
200b/200a/429 cluster-transduced MDA-MB-231 cells, the miR-
141/200c cluster-transduced MDA-MB-231 cells exhibited a 
significant increase in vascular endothelial growth factor (VEGF)-A 
secretion and integrin-alphaV (integrin-αV) expression. 
Treatment with an anti-VEGF-A-neutralizing antibody inhibited 
the increase in migration and invasion and significantly reduced the 
phosphorylation of FAK and AKT in the miR-200b/200a/429- or 
miR-141/200c-transduced MDA-MB-231 cells. In the mouse 
xenograft models, LOXL4 knockdown increased the primary tumor 
growth and lung colonization in MDA-MB-231 cells. LOXL4 
knockdown caused a significant increase in the levels of collagen I 
and IV, as well as lysine hydroxylase (PLOD)1, PLOD2, prolyl 4-
hydroxylase subunit alpha (P4HA)1, and P4HA2, which are the key 
enzymes in collagen biogenesis. The collagen bundle thickening was 
observed in LOXL4 knockdown tumors as compared with that of 
control tumors. The OS analysis of the breast cancer patients (n = 
 vii 
584) revealed that low LOXL4 expression and combination of low 
LOXL4 and high collagen I and IV expression were significantly 
correlated with a poor OS, particularly, TNBC patients (n = 101). 
Conclusions: This study demonstrates the miR-141/200c cluster 
promotes the migratory and invasive abilities of MDA-MB-231 
cells through FAK- and PI3K/AKT-mediated signaling by means of 
increased VEGF-A secretion. In addition, the low LOXL4 
expression triggered the ECM remodeling by inducing the collagen 
synthesis, deposition, and structural changes, which resulted in a 
significant promotion of tumor growth and metastasis. LOXL4 might 
be used as a prognostic marker in TNBC patients. 
---------------------------------------- 
Keywords: Triple-negative breast cancer (TNBC), microRNA-200 
(miR-200), vascular endothelial growth factor (VEGF), Lysyl 
oxidase-like 4 (LOXL4), Collagen, Tumor progression, Overall 
survival 
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Overexpression of the miR-141/200c 
cluster promotes the migratory and 
invasive ability of triple-negative 
breast cancer cells through the 
activation of the FAK and PI3K/AKT 










Aberrant expression of microRNAs (miRs), which are small non-
coding RNA molecules consisting of approximately 22 nucleotides, has 
been identified in human cancer, where the miRNA signature is 
associated with specific clinic and biological features [1]. The 
microRNAs related to cancers may act as tumor suppressors or 
oncogenes, depending on the cancer type [2, 3]. The miR-200 family 
member genes are clustered at two locations in the genome: the miR-
200b/200a/429 cluster and the miR-200c/141 cluster [4]. The miR-
200 family members repress the epithelial-to-mesenchymal transition 
(EMT), cancer cell migration, tumor growth, and metastasis by directly 
targeting specific genes, such as ZEB1, Suz12, moesin, and AP-2γ [4, 
5]. In contrast, the miR-200 family members have been shown to 
enhance the migration ability of breast cancer cells and to promote the 
metastatic colonization of breast cancer cells through up-regulating 
the expression of E-cadherin and down-regulating that of ZEB2 and 
Sec23a [6, 7]. In a recent study, high expression of the miR-200 
family was associated with a high probability of relapse, poor survival, 
and distant metastasis in breast cancer patients [8]. The loss of miR-
200c expression has also been related to the induction of an aggressive, 




[9]. Conflicting results have been obtained in studies of the role of 
each miR-200 family member in repressing or enhancing cancer cell 
migration and invasion as well as the tumor growth and metastasis of 
diverse cancers, including breast cancer [10, 11]. 
Triple-negative breast cancer (TNBC), i.e., breast cancer lacking 
estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2) expression, is a highly 
invasive and metastatic form of breast cancer with a generally poorer 
prognosis than that of other breast cancer subtypes [12]. It is 
important to develop new treatment strategies based on a better 
understanding of the underlying mechanisms regulating the aggressive 
behavior of TNBCs. TNBCs express the miR-200 family members at a 
significantly lower level than do other subtypes of breast cancer, such 
as ER-positive or HER2-positive breast cancer [13]. Only a small 
number of the miR-200 target genes that are involved in breast cancer 
cell migration and metastasis have been identified [4-6], and few 
studies of the role of the miR-200ab or miR-200c cluster in human 
TNBC have been conducted. The biological relevance of the function of 
the miR-200ab or miR-200c cluster in human TNBC remains to be 
discovered. 
Synthetic miR-200b directly downregulates vascular endothelial 




induced increase in VEGF, thus inhibiting angiogenesis in diabetic 
retinopathy [14]. Chemokine CCL5 (formerly RANTES) of the CC-
chemokine family, which plays a critical role in local invasion and 
distant metastasis in chondrosarcoma, promotes VEGF expression and 
angiogenesis by downregulating miR200b [15]. miR-200c 
radiosensitized the lung cancer cell line A549 by targeting the VEGF-
VEGFR2 pathway [16]. From these reports, we speculated that the 
overexpression of the miR-200 family can regulate the expression and 
secretion of cytokines and growth factors involving in cell growth and 
migratory and invasive abilities of TNBC cells.  
In the present study, we used MDA-MB-231 cells, a typical 
human TNBC cell line, which were stably transduced with lentivirus. 
We found that the overexpression of the miR-141/200c cluster 
promoted stronger migration and invasion of, as well as VEGF-A 
secretion by MDA-MB-231 cells. Therefore, we investigated, in detail, 
the mechanisms by which two miR-200 family members, the miR-
200b/200a/429 cluster and the miR-141/200c cluster, regulated 
MDA-MB-231 cell migration and invasion. We demonstrate that the 
overexpression of the miR-141/200c cluster in MDA-MB-231 cells 
increased VEGF-A secretion, which enhanced the migratory ability of 
the cells through the activation of focal adhesion kinase (FAK) and the 





















MATERIALS AND METHODS 
1. Cell culture  
The human breast cancer cell lines MCF-7 (ER-positive subtype), 
MDA-MB-231 and HCC-38 (TN subtype) were obtained from the 
Korean Cell Line Bank (Seoul, Korea). Hs578T cells (TN subtype) 
were obtained from ATCC (Manassas, VA, USA). MCF-7 cells were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (WelGENE, 
Daegu, Korea) containing 10% fetal bovine serum (FBS) and 
supplemented with a 1% antibiotic solution containing penicillin and 
streptomycin (Gibco, Auckland, NZ). The MDA-MB-231, HCC-38, 
and Hs578T cells were grown in Roswell Park Memorial Institute 
(RPMI) 1640 medium (WelGENE) containing 10% FBS and 
supplemented with a 1% antibiotic solution containing penicillin and 
streptomycin (Gibco). The MCF-7, MDA-MB-231, HCC-38, and 
Hs578T cells used in this study were authenticated and validated by 
DNA fingerprinting (AmplFLSTR identifiler PCR Amplification kit), 
which was conducted by the Korean Cell Line Bank. 
2. Lentiviral transduction 
Viral vectors containing either the miR-200b/200a/429 cluster 




(GenBank ID: 406985 406933) constructs and the green fluorescent 
protein (GFP) construct were kindly supplied by Dr. Gregory J. Goodall 
of the University of Adelaide (Adelaide, Australia). A viral vector 
(pLenti M1.41) containing GFP was used as a control vector. Lentiviral 
transduction was conducted according to the manufacturer’s 
instructions. Briefly, cells were seeded at a density of approximately 
10-25% confluency (1 × 105 cells) in 6-well plates and were 
maintained at 37°C with 5% CO2. Following an overnight culture, the 
culture medium was removed. Aliquots of the lentiviral stocks 
containing the miR-200b/200a/429 cluster or the miR-141/200c 
cluster construct as well as the control virus were gently mixed with 8 
μg/ml polybrene and added to each well. After 6 hours of transduction, 
the medium was replaced with fresh complete medium. Transduced 
cells with a cell density of greater than 90% confluency were selected 
using medium containing 3 μg/ml puromycin for 2 weeks. Then, the 
GFP-positive cells were sorted from the selected cells using a 
FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, 
USA). Cancer cells stably expressing the miR-200b/200a/429 cluster 
or the miR-141/200c cluster and GFP, denoted as miR-200ab cells 




pLenti M1.41 vector, denoted as control cells, were generated and 
expanded for use in all subsequent studies. 
3. Quantitative real-time PCR 
TaqMan MicroRNA Assays (Applied Biosystems, South San Francisco, 
CA, USA) were used to quantify the levels of mature miRNAs, 
following the manufacturer’s instructions. The miRNAs were isolated 
from cells using the mirVana miRNA isolation kit (Applied Biosystems), 
and the specific primers for detecting miR-200a, miR-200b, and, 
miR-200c were purchased from Applied Biosystems. Reverse 
transcription was performed using the TaqMan microRNA reverse 
transcription kit (Applied Biosystems) according to the manufacturer’s 
instructions. The traditional TaqMan Assay control, 18s rRNA, was 
used as the endogenous control. Each TaqMan Assay was conducted in 
triplicate. 
4. Reverse transcriptase polymerase chain reaction (RT-PCR) 
The total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, 
CA, USA) and reverse-transcribed using random hexamers and 
Superscript III reverse transcriptase. The cDNAs were synthesized 
using M-MLV reverse transcriptase (New England Biolabs, Ipswich, 




family-transduced cells and non-transduced cells, referred to as the 
control, were evaluated using the conventional RT-PCR method with 
the following primer sets: E-cadherin (421 bp), F, 
ATTCTGATTCTGCTGCTCTTG and R, 
AGTAGTCATAGTCCTGGTCTT; Vimentin (247 bp), F, 
CCCTCACCTGTGAAGTGGAT and R, TCCAGCAGCTTCCTGTAGGT; 
ZEB1 (150 bp), F, TTCAAACCCATAGTGGTTGCT and R, 
TGGGAGATACCAAACCAACTG; ZEB2 (127 bp), F, 
CAAGAGGCGCAAACAAGC and R, GGTTGGCAATACCGTCATCC; 
Snail (557 bp), F, CAGACCCACTCAGATGTCAA and R, 
CATAGTTAGTCACACCTCGT; Fibronectin (171 bp), F, 
CAGAATCCAAGCGGAGAGAG and R, CATCCTCAGGGCTCGAGTAG; 
and β-actin (335 bp), F, TTCCTGGGCATGGAGTCCTGTGG, and R, 
CGCCTAGAAGCATTTGCGGTGG. Each target gene was amplified 
using a Thermocycler (BioRad, Hercules, CA, USA). The PCR products 
were subjected to electrophoresis through 1.5% agarose gels, and the 
levels of gene expression were normalized to that of β-actin. 
5. Cell viability and proliferation assay 
In vitro cell viability and proliferation were assessed using the 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 




environment in 5% CO2 at 37°C in 96-well culture plates. At 1 d, 3 d, 
and 5 d after cell seeding, the MTT solution (a final concentration of 1 
mg/ml) was added, and the cells were incubated for 1 h. At the end of 
the incubation period, the MTT solution was carefully removed, and 
150 µl of dimethyl sulfoxide was added to each well. The plates were 
maintained on a rocker shaker for 10 min at 25°C, and then the amount 
of MTT formazan crystals formed by the viable cells was determined 
using a spectrophotometer based on the absorbance at 540 nm (GE 
Healthcare, Piscataway, NJ, USA). Flow cytometry analysis using 7-
AAD was performed to confirm cell viability.  
6. Migration and invasion assay 
To assess the cell migratory ability, 2-5 × 104 cells were suspended in 
100 μl of medium with or without 10% FBS and deposited in the upper 
chambers of a trans-well plate with 8.0-µm pores (BD Biosciences) 
with a non-coated membrane. For the invasion assays, 5 × 104 cells 
were plated in 2% Matrigel™ (BD Biosciences) basement membrane 
matrix-coated upper chambers in a trans-well plate with 8.0-µm 
pores. The lower chambers were filled with 600 µl of medium 




37°C in the presence or absence of an FAK inhibitor (5 μM PF573228, 
Sigma, St. Louis, MO, USA), a PI3K/AKT inhibitor (20 μM LY294002, 
Cell Signaling Technology, Danvers, MA, USA), 5 μg/ml VEGF-
neutralizing antibody (Santa Cruz Biotechnology, Dallas, TX, USA) or 
10 ng/ml VEGF-A protein (Sigma). Each inhibitor, VEGF-neutralizing 
antibody, or VEGF-A were added in both the upper and lower 
chambers. No chemoattractants were used in the lower chamber for 
either the migration or invasion assays. The cells that migrated from 
the upper chamber were stained using a crystal violet solution (0.5% 
crystal violet in 20% methanol) for 5 min. Unbound crystal violet was 
removed by rinsing using distilled water. The cells were subsequently 
air–dried, and the crystal violet was eluted from the cells using a 
solution of 1% sodium dodecyl sulfate (SDS). The absorbance of 
crystal violet at 550 nm was measured using a spectrophotometer (GE 
Healthcare). 
7. Wound-healing assay 
Cells were seeded at 5 × 104 cells per well in six-well plates and 
cultured under permissive conditions until reaching 90% confluence. 
After 24 h, each confluent cell monolayer was lightly and quickly 




debris was removed, and the edge of the scratch was smoothed by 
washing with PBS. The cells were cultured for 6 h in complete medium, 
after which, the lateral migratory activity was evaluated based on the 
area occupied by the cells that had entered the scratch line at 0 h. 
Images were acquired using a microscope (Leica, Wetzlar, Germany) 
equipped with a CCD camera (Leica). The migration rates were 
calculated according to the equation percentage wound healing = 
[(wound length at 0 h) - (wound length at 6 h)] / (wound length at 0 h) 
× 100. The mean results of three straight distances (upper edge, 
middle, and lower edge) in scratch area were evaluated as wound 
lengths. Length quantification was performed using ImageJ software 
(NIH, Bethesda, MD, USA). 
8. Measurement of cytokines and growth factors 
Samples of 1-2 × 105 cells were seeded in 6-well plates. After a 
two-day culture period, when cells were at 90% confluency, the 
conditioned medium was harvested. The levels of secreted cytokines 
and growth factor (IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, GM-CSF, 
IFN-γ, and VEGF-A) were quantified using the Bio-Plex200 
multiplex array system according to the recommended protocol (Bio-




9. Western blotting 
The cells were lysed in RIPA buffer (Sigma). The proteins were 
separated using SDS-polyacrylamide gel electrophoresis and were 
transferred to nitrocellulose membranes. The membranes were 
blocked using 5% skim milk in Tris-buffered saline containing Tween 
and incubated with primary antibodies directed against ERK, phospho-
ERK, AKT (anti-rabbit polyclonal antibody, Cell Signaling Technology), 
phospho-AKT (anti-mouse polyclonal antibody, Cell Signaling 
Technology), FAK (anti-rabbit polyclonal antibody, Invitrogen), 
phospho-FAK (anti-rabbit polyclonal antibody, Invitrogen), integrin-
αV (anti-rabbit polyclonal antibody, Santa Cruz Biotechnology) or β-
actin (anti-mouse polyclonal antibody, Sigma) overnight at 4°C. The 
membranes were then incubated with horseradish peroxidase-
conjugated secondary antibodies (Santa Cruz Biotechnology). The 
blotted membranes were visualized using enhanced chemiluminescence 
reagents (GE Healthcare). Western blot quantification was performed 
using ImageJ software. 
10. Immunofluorescence staining 
The cells were seeded on sterile cover slips in 24-well plates. Then, 




Cleveland, OH, USA). Primary antibodies directed against integrin-αV 
(Santa Cruz Biotechnology) and phospho-FAK (Invitrogen) were 
applied overnight at 4°C. The bound integrin-αV and phospho-FAK 
antibodies were visualized using secondary antibodies conjugated to 
Alexa 594, and the nuclei were counterstained using 4',6-diamidino-
2-phenylindole (DAPI). All multicolor fluorescence images were 
obtained using a confocal laser-scanning microscopy (LSM5 Meta) 
(Carl Zeiss, Oberkochen, Germany).  
11. Statistical analyses 
For the entire dataset obtained in this study, the mean values ± 
standard deviations were calculated from the results of at least three 
independent experiments and were statistically evaluated using a one-
way ANOVA followed by the t-test. For all tests, p-values of less 









Overexpression of the miR-200b/200a/429 cluster or the miR-
141/200c cluster enhanced the migratory and invasive abilities of MDA-
MB-231 cells 
We first investigated alterations in the characteristics of two different 
breast cancer cell lines, MCF-7 and MDA-MB-231 cells, caused by 
the stable transduction of constructs encoding miR-200 family 
members and GFP using lentiviruses. The GFP-positive cells 
comprised more than 95% of the miR-200b/200a/429 cluster- or 
miR-141/200c cluster-transduced MCF-7 and MDA-MB-231 cells 
(Figure 1-1 and 1-2). Strong GFP expression in the miR-
200b/200a/429 cluster- or miR-141/200c cluster-transduced MCF-
7 and MDA-MB-231 cells was evaluated using microscopy (Figure 
1-1A and 1-3A). RT-PCR was used to evaluate expression levels of 
EMT markers, and the results showed that the overexpression of the 
miR-200b/200a/429 cluster or the miR-141/200c cluster resulted in 
the induction of E-cadherin expression and a decrease in ZEB-1 
expression in MDA-MB-231 cells (Figure 1-1B). Overexpression of 
the miR-200ab or miR-200c cluster led to increased expression of 
Snail in MCF-7 and MDA-MB-231 cells.  




miR-200c in miR-200b/200a/429 cluster- or miR-141/200c cluster-
transduced MDA-MB-231 cells, real-time RT-PCR was conducted to 
quantify the levels of the mature microRNAs. As expected, the miR-
200b/200a/429 cluster- and miR-141/200c cluster-transduced 
MDA-MB-231 cells showed increased mature miR-200a, miR-200b, 
and miR-200c levels at 5-100-fold higher levels than did the control 
MDA-MB-231 cells, which exhibited undetectable levels of all 
members of the miR-200 family (Figure 1-3B).  
To investigate whether overexpression of the miR-200b/200a/429 
or miR-141/200c cluster affected cell growth, an MTT assay was 
performed. Figure 3C shows that the growth rate of the miR-
200b/200a/429 cluster- or miR-141/200c cluster-transduced MDA-
MB-231 cells was similar to that of the control cells on the 3rd day but 
was significantly decreased on the 5th day after cell seeding compared 
with that of the control cells (control vs. miR-200ab, P = 0.02 and 
control vs. miR-200c, P = 0.0002) (Figure 1-3C). The 
overexpression of the miR-141/200c cluster was found to more 
strongly suppress the growth of MDA-MB-231 cells.  
We assessed migratory and invasive abilities using a trans-well 
migration assay and a wound-healing assay. The results of crystal 
violet staining showed that the migratory ability of MCF-7 cells was 




significant difference between that of the miR-200b/200a/429 
cluster- or miR-141/200c cluster-transduced MCF-7 cells and 
control cells (Figure 1-1C and 1-1E). The wound-healing assay, 
which demonstrated the lateral migratory ability of MCF-7 cells, 
yielded results similar to those of the trans-well migration assay 
(Figure 1-1D and 1-1F). 
With regard to the trans-well migration and invasion assays of the 
miR-200b/200a/429 cluster- or miR-141/200c cluster-transduced 
MDA-MB-231 cells, after 48 h of incubation without an FBS gradient, 
cell migration significantly increased up to 1.94±0.22-fold and 
2.49±0.08-fold in miR-200b/200a/429 cluster- or miR-141/200c 
cluster-transduced MDA-MB-231 cells, respectively, compared with 
control cells (Figure 1-3D control vs. miR-200ab, P = 0.04 and 
control vs. miR-200c, P = 0.002). To further investigate the 
migratory ability of miR-141/200c cluster-transduced MDA-MB-231 
cells, the trans-well migration assay under the condition of a 10% FBS 
gradient in the upper (0% FBS) and the lower chamber (10% FBS) was 
conducted for 24 h. A significant increase was observed in the 
migratory ability of the miR-141/200c-transduced MDA-MB-231 
cells (1.53±0.30-fold) relative to MDA-MB-231 cells (Figure 1-4, 




Matrigel™ matrix-coated trans-well membranes showed a significant 
increase in the invasive ability of the miR-200b/200a/429 cluster-
transduced cells (1.61±0.31-fold) and miR-141/200c cluster-
transduced cells (1.98±0.40-fold) after 48 h of incubation compared 
with that of control cells (Figure 1-3E, control vs. miR-200ab, P = 
0.0005 and control vs. miR-200c, P = 0.0002). The elevated migration 
and invasion rates were higher in miR-141/200c cluster-transduced 
MDA-MB-231 cells than miR-200b/200a/429 cluster-transduced 
MDA-MB-231 cells. After 6 h of incubation, the transduction of miR-
200b/200a/429 cluster or miR-141/200c cluster did not affect the 
lateral migratory ability of MCF-7 cells, but increased the lateral 
migration up to 2.78±0.11-fold and 1.69±0.11-fold in miR-
200b/200a/429 cluster- or miR-141/200c cluster-transduced MDA-
MB-231 cells, respectively (P = 0.02, Figure 1-1F). In other TNBC 
cell lines, HCC-38 and Hs578T cells, we observed a significant 
increase in trans-well migration ability in both the miR-141/200c 
cluster-transduced HCC-38 cells (1.64±0.11-fold, P < 0.001) and 
miR-141/200c cluster-transduced Hs578T cells (1.76±0.44-fold, P = 
0.0003) compared with the control cells (Figure 1-5A and D). The 
mature miR-200c levels in miR-141/200c cluster-transduced HCC-




control HCC-38 and Hs578T cells, which exhibited undetectable levels 
of miR-200c (P < 0.001, Figure 1-6G and H).  
We found that the overexpression of the miR-200b/200a/429 
cluster or the miR-141/200c cluster resulted in the highest migratory 
capacity in MDA-MB-231 cells compared with the other TNBC cells, 
HCC-38 and Hs578T cells. Therefore, we focused on the regulatory 
mechanisms by which the miR-200b/200a/429 cluster or the miR-
141/200c cluster promoted the migratory and invasive capacities of the 
MDA-MB-231 cell line, as a representative TNBC cell line. 
Overexpression of the miR-200b/200a/429 cluster or the miR-
141/200c cluster enhanced the phosphorylation of FAK and AKT and 
the expression of integrin in MDA-MB-231 cells 
We investigated whether the overexpression of miR-200 family 
members modulated the focal adhesion kinase (FAK), PI3K/AKT, and 
MEK/ERK signaling pathways, which are involved in cell proliferation 
and migration. Representative western blotting results showed that the 
levels of FAK and AKT phosphorylation were greatly increased, but 
the level of ERK phosphorylation was not significantly changed in the 
miR-200b/200a/429 cluster- or miR-141/200c cluster-transduced 
MDA-MB-231 cells (Figure 1-7A, left). The level of phosphorylated 




fold in the miR-200b/200a/429 cluster-transduced cells and miR-
141/200c cluster-transduced cells, respectively (Figure 1-7A, right, 
control vs. miR-200ab, P = 0.01 and control vs. miR-200c, P = 0.09). 
The level of phosphorylated AKT was also increased 2.21±1.06-fold 
and 9.32±11.07-fold in the miR-200b/200a/429 cluster-transduced 
cells and miR-141/200c cluster-transduced cells, respectively 
(Figure 1-7A, right, control vs. miR-200ab, P = 0.19 and control vs. 
miR-200c, P = 0.32). We also observed that the miR-141/200c 
cluster significantly increased the phosphorylation levels of FAK 
(1.98±0.37-fold, P = 0.04) and AKT (5.61±1.73-fold, P = 0.04) in 
HCC-38 cells (Figure 1-8C and D). Representative western blotting 
results showed that the expression levels of integrin-αV, which is 
associated with the FAK signaling pathway, were increased in both the 
miR-200b/200a/429 cluster- and miR-141/200c cluster-transduced 
cells (Figure 1-7B, left). Integrin-αV expression was increased 
1.57±0.10-fold and 1.70±0.24-fold in the miR-200b/200a/429 
cluster-transduced cells and miR-141/200c cluster-transduced cells, 
respectively (Figure 1-7B, right, control vs. miR-200ab, P = 0.01 and 
control vs. miR-200c, P = 0.04). Integrin-αV expression was also 




transduced HCC-38 cells (Figure 1-8C and D). To investigate the 
cellular localization of phosphorylated FAK and integrin-αV, 
immunofluorescent staining was assessed. Phosphorylated FAK was 
largely localized at the focal adhesions of the plasma membranes of the 
miR-200b/200a/429 cluster- and miR-141/200c cluster-transduced 
cells (Figure 1-7C). Integrin-αV accumulated and clustered at the 
periphery of the plasma membranes of the miR-200b/200a/429- and 
miR-141/200c-transduced cells compared with that in control cells 
(Figure 1-7C). The levels of FAK phosphorylation and integrin-αV 
expression were higher in the miR-141/200c cluster-transduced 
HCC-38 cells than in the control cells (Figure 1-8E). 
To determine the signaling pathway involved in enhanced 
migratory and invasive ability of miR-200b/200a/429 cluster- or 
miR-141/200c cluster-transduced MDA-MB-231 cells trans-well 
migration assays were performed in the presence of PF573228 or 
LY294002, which are chemical inhibitors of FAK and PI3K/AKT, 
respectively. The chemical inhibitors were added to both the upper and 
lower chambers, which would allow their effects to last throughout the 
entire experimental period. The enhanced migratory activity was 
completely inhibited in miR-200b/200a/429 cluster- and miR-




FAK or PI3K/AKT inhibitor, reaching the basal migratory level of 
MDA-MB-231 cells (Figure 1-7D). These observations 
demonstrated that the elevated migratory ability of MDA-MB-231 
cells by stable overexpression of miR-200b/200a/429 cluster or 
miR141/200c cluster was driven by the activation of the FAK and 
PI3K/AKT-mediated signaling pathways. 
Overexpression of the miR-200b/200a/429 cluster or the miR-
141/200c cluster increased the level of VEGF-A secretion in MDA-
MB-231 cells 
The secreted cytokines or growth factors that might be involved in 
regulating the migration of the miR-200b/200a/429 cluster- or 
miR141/200c cluster-transduced cells were analyzed. The levels of 
IL-2, GM-CSF, and IFN-γ secreted into the medium by the miR-
200b/200a/429 cluster- and miR-141/200c cluster-transduced 
MDA-MB-231 cells after 48 h of culture were lower than those of the 
control MDA-MB-231 cells. However, the secreted VEGF-A levels 
were significantly higher in the conditioned medium of the miR-
200b/200a/429 cluster-transduced cells (1.64±0.03-fold) and miR-
141/200c cluster-transduced cells (2.66±0.09-fold) than in that of the 
control MDA-MB-231 cells (Figure 1-9A, control vs. miR-200ab, P 




of VEGF-A was higher in miR-141/200c cluster-transduced cells 
than miR-200b/200a/429 cluster-transduced cells (miR-200ab vs. 
miR-200c, P = 0.0001). The secreted levels of cytokines and growth 
factors were also evaluated in the miR-141/200c cluster-transduced 
HCC-38 and Hs578T cells. VEGF-A secretions were significantly 
increased in miR-141/200c cluster-transduced HCC-38 (1.75±0.03-
fold, P = 0.00001) and miR-141/200c cluster-transduced Hs578T 
cells (1.17±0.16-fold, P = 0.004) relative to control cells (Figure 1-
5B and E). The effect of miR-141/200c overexpression on increased 
cell migration and VEGF-A secretion was greater in MDA-MB-231 
cells relative to HCC-38 and Hs578T cells. There were no definite 
differences in VEGF-A secretion levels between the miR-141/200c 
cluster–transduced Hs578T and the control Hs578T cells. These 
results were explained by the phenotypic and functional heterogeneity 
among cancer cells in TNBC cells. The VEGF-A expression levels 
were also examined in the miR-200b/200a/429 cluster- or 
miR141/200c cluster-transduced MDA-MB-231 cells, but the 
transduction of miR-200b/200a/429 cluster (1.18±0.31-fold) or miR-
141/200c cluster (0.90±0.34-fold) did not affect VEGF-A expression 
(Figure 9B, right, control vs. miR-200ab, P = 0.38 and control vs. 




cells (0.92±0.09-fold) also expressed VEGF-A levels that were 
similar to the control HCC-38 cells (Figure 1-8A, P = 0.46). 
Blocking VEGF-A activity inhibited the enhanced migration and invasion 
of miR-200b/200a/429 cluster or miR-141/200c cluster-transduced 
MDA-MB-231 cells  
To examine whether secreted VEGF-A regulates the migratory and 
invasive abilities of the miR-200b/200a/429 cluster- or miR141/200c 
cluster-transduced MDA-MB-231 cells, trans-well migration and 
invasion assays were performed after treatment with anti-VEGF-A-
neutralizing antibodies. The anti-VEGF-A-neutralizing antibodies 
were added to both the upper and lower chamber, which would allow 
their effects to last throughout the entire experimental period. Figures 
1-9C and D showed that the anti-VEGF-A-neutralizing antibodies 
completely inhibited the increased migratory (control vs. miR-200ab, 
P = 0.0001 and control vs. miR-200c, P = 0.002) and invasive 
(control vs. miR-200ab, P = 0.02 and control vs. miR-200c, P = 
0.001) abilities of the miR-200b/200a/429 cluster- and miR-
141/200c cluster-transduced cells. These data clearly indicated that 
secreted VEGF-A was involved in promoting the migration and 
invasion of both miR-200b/200a/429 cluster- and miR141/200c 
cluster-transduced cells. The administration of anti-VEGF-A-




migration increased by miR-141/200c overexpression in both the 
miR-141/200c cluster-transduced HCC-38 and miR-141/200c 
cluster-transduced Hs578T cells (Figure 1-5C and F). The anti-
VEGF-A-neutralizing antibodies also completely inhibited the 
increased migratory ability (control vs. miR-200c, P < 0.001) of the 
miR-141/200c cluster-transduced HCC-38 cells (Figure 1-5C, 
untreated vs. VEGF-A Ab, P < 0.001).  
These results supported that VEGF-A secretion was associated 
with enhancing migration ability in TNBC cells. The anti-VEGF-A-
neutralizing antibodies partly blocked the enhanced migratory ability 
(control vs. miR-200c, untreated, 1.76±0.44-fold, P = 0.0003) of both 
the control (0.80±0.07-fold, P = 0.003) and the miR-141/200c 
cluster-transduced Hs578T cells (1.37±0.21-fold, P = 0.003), but the 
miR-141/200c cluster-transduced Hs578T cells still showed 
increased migratory ability compared with that of the control cells 
(control vs. miR-200c, VEGF-A Ab treated, P < 0.001, Figure 1-5F). 
These results imply that other factors besides VEGF-A may also be 
involved in promoting migration in miR-141/200c cluster-transduced 
Hs578T cells. 
The miR-141/200c cluster activated the FAK and PI3K/AKT signaling 




migratory and invasive abilities of MDA-MB-231 cells 
To ascertain the VEGF-A-mediated intracellular signaling pathway 
responsible for the increased migratory and invasive abilities of miR-
200b/200a/429 cluster- or miR141/200c cluster-transduced MDA-
MB-231 cells, the levels of FAK and AKT phosphorylation were 
evaluated in cells treated with 5 μg/ml anti-VEGF-A-neutralizing 
antibodies. Treatment with anti-VEGF-A-neutralizing antibodies for 
both 30 min and 48 h remarkably decreased the level of FAK and AKT 
phosphorylation in the miR-141/200c cluster-transduced MDA-MB-
231 cells and the control cells but did not affect the level of 
phosphorylated FAK and AKT in the miR-200ab cluster-transduced 
MDA-MB-231 cells (Figure 1-9E and F). In contrast, the level of 
ERK phosphorylation was increased by anti-VEGF-A-neutralizing 
antibodies in miR-141/200c-transduced cells and control cells. These 
data implied that FAK and AKT acted as a direct link between elevated 
VEGF-A secretion and the consequential signal transduction related to 
enhanced migration of miR-141/200c cluster-transduced MDA-MB-
231 cells, but the increased secretion of VEGF-A in miR-
200b/200a/429 cluster-transduced MDA-MB-231 cells was not 
directly followed by activation of the FAK and AKT-mediated 





Exogenous VEGF-A stimulated migration of MDA-MB-231 cells by 
activating the FAK and PI3K/AKT pathway 
To confirm the role of VEGF-A as a migration-activating mediator in 
miR-200b/200a/429 cluster- or miR-141/200c cluster-transduced 
MDA-MB-231 cells, a trans-well migration assay was assessed in 
MCF-7 and MDA-MB-231 cells treated with exogenous VEGF-A 
protein. The representative crystal violet staining of exogenous 
VEGF-A (10 ng/ml)-treated MCF-7 and MDA-MB-231 cells that 
had migrated through the trans-well membranes after 48 h is shown in 
Figure 1-10A. A quantitative analysis of a crystal violet assay showed 
that exogenous VEGF-A significantly increased MDA-MB-231 cell 
migration up to 1.50±0.16-fold but had no effect on the migratory 
ability of MCF-7 cells compared with that of untreated cells (Figure 
1-10B, untreated vs. VEGF-A, P = 0.003). In addition, we 
investigated whether VEGF-A played a role as a migration-activating 
mediator in HCC-38 cells. As expected, VEGF-A treatment 
significantly increased HCC-38 cell migration up to 1.56±0.26-fold 
(Figure 1-11B, untreated vs. VEGF-A, P < 0.001). 
To verify the exogenous VEGF-A-mediated intracellular signaling 
pathways responsible for the increased migratory ability of MDA-MB-




evaluated. After cell starvation for 4 h, treatment with exogenous 
VEGF-A for 15 min, 30 min, 60 min, and 48 h induced the periodic 
fluctuation of the phosphorylation levels of FAK and AKT and 
generally increased phosphorylated FAK and AKT, but did not affect 
the phosphorylation level of ERK in MDA-MB-231 cells (Figure 1-
10C and D). These data indicated that the activation of the FAK and 
PI3K/AKT signaling pathways mediated by the exogenous VEGF-A 
increased the migratory ability of MDA-MB-231 cells. Similar results 
that VEGF-A stimulated FAK, AKT, and ERK were also observed in 














The role of miR-200 family in regulating the migration and invasion of 
different cancer cell types is controversial [10, 11]. Moreover, only a 
small number of miR-200 target genes that regulate cell migration and 
cancer metastasis has been identified [4, 6], and the mechanisms 
underlying the functions of miR-200b/200a/429 cluster and miR-
141/200c cluster in TNBC cells are not fully understood. It is well-
known that the miR-200 family expression levels are significantly 
lower in highly migratory TNBC cells and metastatic TNBC tumors 
than other types of breast cancer cells and tumors. In addition, Vrba L 
et al. reported that the repression of miR-200 and miR-141 
expression due to aberrant epigenetic gene silencing in aggressive 
cancer cells, including MDA-MB-231 cells, indicating that the 
downregulation of miR-200 may contribute to an aggressive TNBC 
phenotype [17]. ZEB1 and SIP1 have been found to repress primary 
transcript and mature miR-200 expression in mesenchymal types of 
breast cancer cells, suggesting a downregulation of miR-200 in TNBC 
cells through a potential double-negative feedback loop between 
ZEB1/SIP1 and the miR-200 family [18]. Manav K et al. reported the 
highest expression of miR-200s in the highly metastatic 4T1 cells, a 
mouse TNBC cell line, which was consistent with acquisition of 




4TO7 cells. In addition, 4T1 tumors exhibit spontaneous metastasis 
and colonization of distant organs, which is enhanced by miR-200 
overexpression in experimental animal models; furthermore, higher 
expression of miR-200 levels were found in lung-pleural metastasis 
samples relative to primary tumor samples in breast cancer patients. 
These data support the potential role of miR-200s in migration, 
invasion, metastatic colonization, and metastatic dissemination [6]. 
Recently, Avery-Kiejda KA et al. found that the miR-200 cluster is 
upregulated in invasive ductal carcinomas with both lymph node-
positive and lymph node-negative TNBC compared with matched 
normal adjacent tissues [19]. Their reports of in vivo experimental and 
clinical evidence may indicate that tumor cell populations with 
increased aggressiveness may have higher miR-200 cluster levels 
than their less aggressive counterparts within the same TNBC and in 
normal tissues; the miR-200 cluster, though being generally reduced 
in TNBC compared with other subtypes, is upregulated in TNBC cells 
that may support metastatic dissemination. We showed here that the 
overexpression of miR-200b/200a/429 cluster or miR-141/200c 
cluster strongly promoted the migration and invasion of MDA-MB-
231, HCC-38, and Hs578T cells, typical claudin-low and 
mesenchymal subtypes of TNBC cell lines [20], compared with those 
of an ER-positive breast cancer cell line, MCF-7 cells. The migratory 




enhanced in those that overexpressed the miR-141/200c cluster than 
in those with the miR-200b/200a/429 cluster. These data suggest that 
the different roles of the miR-200 family members, such as miR-200a, 
miR-200b, miR-200c, miR-141, and miR-429, on the migration and 
invasion of different subtypes of human breast cancer cell lines 
classified by molecular characterization should be further investigated 
[21].  
Dysregulation of the PI3K/AKT signaling pathway has been 
implicated in mammary carcinogenesis and was suggested to be the 
mechanism underlying the survival of invasive breast cancer cells [22]. 
Furthermore, an activated AKT signaling pathway, a common 
dysregulation observed in breast cancers, has been shown to promote 
cancer cell growth, survival, and metastasis [23]. FAK is a cytoplasmic 
tyrosine kinase that plays crucial roles in integrin-mediated signal 
transduction, and FAK localizes to the sites where transmembrane 
integrin receptors are clustered to mediate various intracellular signal-
transduction pathways [5, 24]. Many recent studies have reported that 
an increased level of FAK expression highly correlates with the 
invasiveness and metastasis of human tumors [25-27]. We found that 
the phosphorylation levels of AKT and FAK in MDA-MB-231 cells 
were elevated by stable overexpression of the miR-200b/200a/429 




integrin-αV and phosphorylated FAK co-localized in the 
transmembrane of miR-200b/200a/429 cluster- and miR-141/200c 
cluster-transduced MDA-MB-231 cells. These data suggest that the 
stable overexpression of the 200b/200a/429 cluster and the miR-
141/200c cluster in MDA-MB-231 cells may affect the secretion of 
cytokines or growth factors to activate FAK or the PI3K/AKT signaling 
pathway. The regulation between the miR-200 family and FAK is not 
fully understood. A model indicating that a stiffer matrix of breast 
cancers will activate FAK, which inhibits the miR-200 family and allow 
for a mesenchymal phenotype has been proposed [28]. This model is 
not consistent with our observation that the overexpression of the 
miR141/200c cluster or the miR-200b/200a/429 cluster increased 
clustering and expression of integrins and activated FAK and AKT, 
which regulate cell migration. Our finding proposes a positive cross-
talk between FAK and overexpressed miR-200 in TNBC cells. 
Many studies have been aimed at understanding the role of 
cytokines and growth factors in breast cancer progression. Some 
cytokines and growth factors (IL-1, IL-6, IL-11, TGF- β, and VEGF) 
stimulate the proliferation and invasion of breast cancer cells, whereas 
others (IL-12, IL-18, and IFN) suppress breast cancer progression 
[29]. A recent study reported that miR-200 inhibits angiogenesis by 




cells [30]. Our study demonstrated that the overexpression of the 
miR-200b/200a/429 cluster or the miR-141/200c cluster in MDA-
MB-231 cells led to a decrease in the secretion of IL-2, IL-4, IL-5, 
IL-10, IL-13, GM-CSF, INF-γ and TNF-α but a significant increase 
in the secretion of VEGF-A. VEGF has been reported to activate the 
PI3K/AKT/forkhead signaling pathway to promote angiogenesis in 
human endothelial cells [31]. In addition, VEGF-A, the most potent 
angiogenic factor in tumor angiogenesis, induces oligodendrocyte 
precursor cell migration through a ROS- and FAK-dependent 
mechanism [32]. VEGF-A is known to be a direct target of miR-200b 
[33], but in our results, a significant decrease in VEGF-A levels 
assessed by western blotting was not observed in miR-
200b/200a/429- and miR-141/200c-transduced MDA-MB-231 cells 
or in miR-141/200c-transduced HCC-38 cells relative to control. 
Moreover, VEGF-A secretions in MDA-MB-231, HCC-38, and 
Hs578T cells were increased by the overexpression of the miR-
141/200c cluster. The comprehensive interactions between miRNAs 
and transcription factors (TFs) are expected to comprise “wired” 
genetic networks to regulate the expression of target genes [34]. In 
examples of an incoherent feed-forward loop, the direct regulatory 
effect of TFs on the target gene (VEGF-A) is opposed to the indirect 




comprehensive interactions between miRNAs and protein-coding 
genes, we propose that miR-200 overexpression in TNBC cells can 
affect TFs (HIF-1, CREB) or signals (PI3K/AKT) to regulate VEGF-
A secretion through an incoherent feed-forward loop. An autocrine 
loop for VEGF-A to induce breast cancer cell migration/invasion has 
been well documented [35, 36]. From these reports, we assume that 
the VEGF-A secreted by miR-200 overexpression interacts with its 
receptors, such as neuropilin-1 (NP-1) and VEGFR, and stimulates 
the PI3K/AKT signaling pathway, thus promoting TNBC cell migration 
and invasion. In this study, we demonstrated that treatment with 
VEGF-A led to an increase in migratory ability and activated FAK and 
the PI3K/AKT signaling pathway in MDA-MB-231 cells and HCC-38 
cells. Our results strongly support that VEGF-A-mediated FAK or 
PI3K/AKT signaling pathway modulates cancer cell migration and 
invasion. By down-regulating miR-200b expression through the 
PI3K/AKT signaling pathway, the chemokine CCL5 (formerly RANTES) 
promotes VEGF-dependent angiogenesis in human chondrosarcomas 
[15]. In addition, synthetic miR-200c downregulates VEGF-A by the 
direct targeting of the 3’UTR of VEGF-A mRNA in a lung cancer cell 
line [16]. Contrary to above studies, in this study, the stable 
overexpression of the miR-200b/200a/429 cluster and the miR-
141/200c cluster in MDA-MB-231 cells resulted in increased VEGF-




PI3K/AKT or FAK signaling pathways using chemical inhibitors 
inhibited the enhanced migration and invasion in MDA-MB-231 cells 
overexpressing the miR-200b/200a/429 cluster or the miR-141/200c 
cluster. Inhibiting the VEGF-A-mediated pathway using anti-VEGF-
A-neutralizing antibodies suppressed the elevated AKT and FAK 
phosphorylation in MDA-MB-231 cells overexpressing miR-
141/200c cluster, reversing the enhanced migratory and invasive 
abilities. These results suggest that the activation of FAK and the 
PI3K/AKT signaling pathway are directly mediated by elevated VEGF-
A secretion, which is involved in the increased migratory and invasive 
abilities of miR-141/200c cluster-transduced MDA-MB-231 cells. 
On the other hand, FAK- and PI3K/AKT-independent signaling 
pathways activated by VEGF-A may lead to an enhanced migratory 
ability in miR-200b/200a/429 cluster-transduced MDA-MB-231 
cells. The present study implies that aberrant expression of miR-
200b/200a/429 cluster or the miR-141/200c cluster may play a pro-















LOXL4 knockdown enhances tumor 
growth and lung metastasis through 
collagen-dependent extracellular 










Elevated collagen deposition and alterations in the structure of the 
extracellular matrix (ECM) are common in various forms of cancer [37, 
38]. In particular, elevated expression and deposition of collagen I and 
IV affects laminin levels and has been implicated in abnormal stiffness 
of the ECM [39]. Aberrant expression of lysyl oxidase (LOX) family 
genes, which catalyze collagen cross-link formation, and of the 
procollagen-lysine 2-oxyglutarate 5-dioxygenase (PLOD) and prolyl 
4-hydroxylase α subunit (P4HA) genes, which mediate collagen lysine 
hydroxylation, also alter the structure of the ECM [40-46]. 
Levels of lysyl oxidase-like 4 (LOXL4) are much lower than levels 
of other LOX family members in various normal tissues [47]. In 
addition, the associations between aberrant LOXL4 expression and its 
pathophysiological effects in cancer are similar to those observed for 
other LOX family members [48-53]. However, previous reports have 
obtained conflicting results regarding the effects of LOXL4 in cancer. 
In bladder cancer, LOXL4 suppresses tumors by inhibiting the 
oncogenic signaling pathway [52]. In contrast, LOXL4 promotes 
aggressive tumor progression and metastasis in colorectal and oral 
cancers [53, 54]. In breast cancer, LOXL4, LOX, and LOXL2, which are 




bone marrow-derived cells and facilitate colonization of the lungs [55]. 
These conflicting results might be explained by differences in the 
cellular context among cancers that might influence whether LOXL4 
acts as a tumor suppressor or a metastasis promoter. Although many 
studies have been conducted to elucidate the role of LOXL4 in cancer, 
the precise mechanisms by which LOXL4 suppresses tumors or 
promotes metastasis in breast cancer remain largely unknown. Clinical 
studies have shown that high LOX and LOXL2 expression are 
correlated with increased metastasis and poor survival in triple 
negative breast cancer (TNBC) patients [56, 57]. Interestingly, a 
recent report revealed that, among the LOX family members, LOXL4 
mRNA levels alone were higher in cancer tissues from TNBC patients 
than in those from estrogen receptor-positive breast cancer patients 
[58]. Although these reports suggest that LOXL4 expression might 
affect clinical outcomes in TNBC patients, to the best of our knowledge, 
no studies have directly examined this relationship. Here, we injected 
mice with LOXL4-knockdown MDA-MB-231 cells, which are 
aggressive TNBC cells, to investigate the roles of LOXL4 in primary 
tumor growth and metastasis in a xenograft model. In addition, we 
evaluated the clinical significance of LOXL4 in human breast cancer 





MATERIALS AND METHODS 
1. Cell lines  
The human breast cancer cell lines MCF-7, BT-474, MDA-MB-453, 
SK-BR3, HCC1954, BT-549, MDA-MB-157, MDA-MB-231, MDA-
MB-468, and HCC1937, and normal breast epithelial cells MCF-10A, 
were obtained from ATCC (Manassas, VA, USA) or the Korean Cell 
Line Bank (Seoul, Korea). The breast cancer cells used in this study 
were authenticated and validated by DNA fingerprinting (AmpFLSTR 
identifier PCR Amplification kit), which was conducted by the Korean 
Cell Line Bank or provided by the distributors. 
2. Lentiviral transduction 
Viral vectors containing either the TRIPZ-inducible lentiviral non-
silencing shRNA control as a negative control vector or a TRIPZ-
inducible LOXL4 shRNA (shLOXL4: clone ID V2THS_138014) 
construct and the red fluorescent protein (RFP) construct were 
purchased from GE Dharmacon (Pittsburgh, PA, USA). Lentiviral 
transduction was conducted according to the manufacturer’s 
instructions. RFP-positive cells were selected from cultures 
maintained in medium containing 0.5-3 μg/mL puromycin for 2 weeks; 




(BD Biosciences, Franklin Lakes, NJ, USA) and cultured in medium 
without puromycin. Cancer cells that stably expressed RFP and either 
the non-silencing shRNA or the LOXL4 shRNA, denoted control cells 
and shLOXL4 cells, respectively, were generated for use in all 
subsequent studies. Viral vectors containing the luciferase and green 
fluorescent protein (GFP) constructs were also transduced for the 
animal study using the same procedure described above. GFP-positive 
cells were then selected and sorted using a FACSCalibur flow 
cytometer. 
3. RNA isolation and quantitative real-time PCR 
Total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, 
CA, USA) and was reverse-transcribed using random hexamers and 
Superscript III reverse transcriptase. cDNAs were synthesized using 
M-MLV reverse transcriptase (New England Biolabs, Ipswich, MA, 
USA) and random primers. mRNA levels were measured in control and 
shLOXL4 cells using the quantitative real-time method and the 
following primer sets: LOX (174 bp) F, GTTCCAAGCTGGCTACTC, 
and R, GGGTTGTCGTCAGAGTAC; LOXL1 (244 bp) F, 
CAGACCCCAACTATGTGCAA, and R, ATGCTGTGGTAATGCTGGTG; 
LOXL2 (239 bp) F, GGAAAGCGTACAAGCCAGAG, and R, 
GCACTGGATCTCGTTGAGGT; LOXL3 (162 bp) F, 




LOXL4 (165 bp) F, ACCGAAGACAAAGCCACAAC, and R, 
CACACGACACTGGCAGAGAT; and β-actin (335 bp) F, 
TTCCTGGGCATGGAGTCCTGTGG, and R, 
CGCCTAGAAGCATTTGCGGTGG. Relative gene expression was 
determined using an ABI 7500 real-time polymerase chain reaction 
(PCR) instrument (Applied Biosystems, South San Francisco, CA, USA) 
with pre-optimized conditions. PCR reactions were performed in 
triplicate. Expression ratios were calculated as the normalized 
threshold cycle (Ct) difference between the control and samples after 
adjustment for amplification efficiency relative to expression of the 
housekeeping gene β-actin.  
4. Cell viability and proliferation assay 
In vitro cell viability and proliferation were assessed using the 3-(4, 
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
assay. One, 3, and 5 days after cell seeding, MTT solution (final 
concentration 1 mg/mL) was added, and cells were incubated for 1 h. 
The medium was then carefully removed and the dimethyl sulfoxide 
was added to each well. The amount of formazan crystals formed by 
viable cells was determined by measuring absorbance at 540 nm with a 
spectrophotometer (GE Healthcare, Piscataway, NJ, USA). 




Breast cancer cells were trypsinized to generate single cell 
suspensions and seeded at a low density (500 cells/well in 96-well 
plates) in Dulbecco's Modified Eagle's Medium-F12 supplemented with 
B-27 (Invitrogen) , 20 ng/mL epidermal growth factor (BD 
Biosciences), 10 ng/mL leukemia inhibitory factor (Invitrogen), and 20 
ng/mL basic fibroblast growth factor (BD Biosciences). Seven to 14 
days later, average numbers of colonies per well were calculated. 
These experiments were performed in triplicate. 
6. Migration and invasion assays 
To assess cell migratory ability, 5 × 104 cells were suspended in 100 
μL of medium containing no FBS and were deposited in the upper 
chambers of a trans-well plate with 8.0-µm pores (BD Biosciences) 
and non-coated membranes. For the invasion assays, 5 × 104 cells 
were plated in 2% Matrigel™ (BD Biosciences) basement membrane 
matrix- or 5 µg/cm2 type I rat tail collagen-coated upper chambers of 
trans-well plates with 8.0-µm pores. The lower chambers were filled 
with 600 µL of medium supplemented with 10% FBS, and the cells 
were incubated for between 24-48 h at 37C depending on the cell 
line. Cells that migrated from the upper chambers to the bottom 




violet in 20% methanol) for 5 min. Unbound crystal violet was removed 
by rinsing with distilled water. The cells were then air dried, after 
which the crystal violet was eluted from the cells using a 1% sodium 
dodecyl sulfate (SDS) solution. The absorbance of the crystal violet 
was measured at 550 nm using a spectrophotometer (GE Healthcare). 
7. Western blotting 
Cells were lysed in RIPA buffer (Sigma, St. Louis, MO, USA), and 
proteins were separated using SDS-polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes. The 
membranes were blocked using 5% skim milk in Tris-buffered saline 
containing 0.1% Tween-20 and incubated with primary antibodies 
directed against LOX, LOXL1, LOXL2, LOXL3 (Santa Cruz 
Biotechnology, Santa CruzCA, USA), LOXL4 (Abcam, Cambridge, MA, 
USA), Collagen I (Novus, Littleton, CO, USA), Collagen IV (Abcam), 
PLOD1, PLOD2, P4HA1, P4HA2 (Novus), or β-actin (Sigma) 
overnight at 4°C. The membranes were then incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies 
(Santa Cruz Biotechnology). The blotted membranes were visualized 
using enhanced chemiluminescence reagents (GE Healthcare). Western 




8. Animals and xenograft tumor models 
All animal experiments were approved by the Seoul National University 
Hospital Biomedical Research Institute Animal Care and Use Committee 
(IACUC). 5- to 6-week-old female BALB/c nude mice were used. 
For the orthotopic xenograft tumor model, a total of 5 × 106 breast 
cancer cells per mouse were resuspended in Matrigel™ and injected 
into the 4th mammary glands of mice. The mice were separated into 
two groups of 5 mice each; group 1 received cells expressing non-
silencing shRNA (control), while group 2 received cells expressing 
inducible LOXL4 shRNA (shLOXL4). No tumors grew in one of the 5 
control group mice; only data from the remaining 4 control group mice 
were used. The lung metastatic tumor models were created by 
administering a total of 5 × 105 breast cancer cells per mouse 
(suspended in phosphate-buffered saline, PBS) into the tail veins of 
mice. The mice were separated into the same two groups described 
above; each group again had 5 mice. To induce LOXL4 knockdown in 
vivo, normal drinking water was replaced with 3% sucrose (added to 
increase palatability) with 2 mg/mL doxycycline (Sigma) and changed 
every 2-3 days. Primary tumor volume after implantation was 
measured using calipers. To determine xenograft tumor volumes, a 




was used in which the length was the largest longitudinal diameter of 
the tumor and the width was the largest transverse diameter of the 
tumor. 
9. Bioluminescent and RFP fluorescence imaging 
To monitor primary tumor growth and metastasis non-invasively, 
bioluminescent imaging (BLI) was conducted on the IVIS 100 system 
(Caliper Life Sciences, Hopkinton, MA, USA). Once each week, the 
firefly luciferase substrate D-luciferin (Promega, San Luis Obispo, CA, 
USA) was injected intraperitoneally at a dose of 150 mg/kg, and 
images of the tumor and lung areas were acquired 10 minutes later to 
evaluate peak intensities. The sum of all detected photon counts within 
oval-shaped regions of interest (ROI, tumor or lung) was quantified in 
units of mean photons per second per square centimeter per steradian 
(p/s/cm2/sr) using Living Image® software (Caliper Life Sciences). 
For ex vivo RFP fluorescence imaging, mice were anesthetized and 
primary tumors and lung tissues were excised. Ex vivo RFP 
fluorescence images were obtained using the Maestro imaging system 
(CRi, Woburn, MA, USA); spectral fluorescence images consisting of 
autofluorescence spectra and spectra from RFP were then unmixed 
based on their spectral patterns using Maestro software (CRi). 




Histological analyses of primary tumors and cancer nodules in the 
lungs were performed. The primary tumors and lungs were removed 6 
or 10 weeks after control or shLOXL4 cells were injected. 
Hematoxylin and eosin (H&E), Masson’s trichrome, or Picrosirius red 
stainings, and immunostaining using primary LOXL1 (Santa Cruz 
Biotechnology), LOXL4 (Abcam), Collagen I (Novus), Collagen IV 
(Abcam), PLOD1, PLOD2, P4HA1, and P4HA2 (Novus) antibodies and 
HRP-conjugated secondary antibodies (Santa Cruz Biotechnology) 
were performed. Histological images of the stained tissues were 
acquired using a microscope (Leica, Buffalo Grove, IL, USA) equipped 
with a CCD camera. 
11. Multiphoton second harmonic generation microscopy and image 
analysis 
Collagen second harmonic generation (SHG) images were collected 
using a two-photon Zeiss LSM 7 MP microscope (Carl Zeiss, Maple 
Grove, MN, USA) with a 20 × lens to assess the degree of collagen 
matrix remodeling. A Ti:sapphire laser (Chameleon, Coherent) was 
used. The excitation wavelength was 930 nm. The collagen SHG signal 
from the H&E-stained slides was collected using a 420-480 nm 
narrow bandpass emission filter. The same laser power and detector 




experiments were conducted for samples from primary tumors of both 
the non-silencing shRNA (control) group and the inducible LOXL4 
shRNA (shLOXL4) group. Different regions were analyzed for each 
independent experiment. A MATLAB (MathWorks, Natick, MA, USA) 
script was written to fit image cross-sections with a spatial correlation 
function. The Curvelet Transform denoising FIbeR Extraction algorithm 
(CT-FIRE, LOCI, University of Wisconsin, Madison, WI, USA), an 
open-source collagen analysis program, was used to automatically 
analyze individual fiber metrics such as length, width, and straightness, 
in the images. 
12. Analysis of the BreastMark dataset 
A public online tool, BreastMark, was used to examine the prognostic 
value of the putative genes in breast cancer patients. This database 
integrates gene expression and survival data from 26 datasets 
generated with 12 different microarray platforms and corresponds to 
approximately 17,000 genes in up to 4,738 samples. Overall survival 
(OS) was analyzed, and the median was used to dichotomize the data 
[59]. Median survival was evaluated in high and low LOXL4, collagen I, 
and collagen IV expression groups; the high expression group included 
the 25% of samples with the highest expression, and the low 
expression group included the 25% of samples with the lowest 




estimates; the log-rank p value with one degree of freedom was used 
to identify differences in survival, and hazard ratios (HR) with 95% 
confidence intervals were computed using Cox regression analysis. A 
hazard ratio of greater than one indicates that the marker was 
associated with poor prognosis, while a ratio of less than one means 
that it was associated with good prognosis. 
13. Statistical analyses 
Mean values ± standard deviations for all data were calculated for the 
results of at least three independent experiments and were statistically 
evaluated using analysis of variance (ANOVA) and paired t-tests. 
Mann-Whitney U test was used for statistical analysis of the in vivo 
BLI lung images because the shLOXL4 population had larger values 
than the control population. For all tests, p-values of less than 0.05 










LOXL2, LOXL3, and LOXL4 expression are higher in MDA-MB-231 
cells than in other human breast cancer cells 
We measured the expression of LOX and LOXL1-4 in a total of 10 
human breast cancer cell (hBCC) lines that are classified as either 
luminal (MCF-7, BT-474), HER2 (MDA-MB-453, SK-BR3, 
HCC1954), or TN (BT-549, MDA-MB-157, MDA-MB-231, MDA-
MB-468, HCC1937) subtype, as well as in normal breast epithelial 
cells (MCF-10A). As shown in Figure 2-1A and C, LOX and LOXL2 
expression were abundant in all of the hBCCs and in the normal breast 
epithelial cells. LOXL1 was highly expressed in both the luminal 
subtype cells (MCF-7, BT-474) and in two of the three HER2 
subtype cells (MDA-MB-453, SK-BR3), but was expressed at very 
low levels in HER2 subtype HCC1954 cells and in the TN subtype cells 
(BT-549, MDA-MB-157, MDA-MB-231, MDA-MB-468, 
HCC1937). In contrast, LOXL3 and LOXL4 expression was higher in 
the TN subtype cells (BT-549, MDA-MB-157, MDA-MB-231, 
HCC1937) than in the other subtypes. Furthermore, LOXL2, LOXL3, 
and LOXL4 expression were higher in MDA-MB-231 cells than in the 
other TN cells (BT-549, MDA-MB-157, MDA-MB-468, HCC1937). 
In addition, LOXL4 expression was higher in MDA-MB-231 cells than 




TN cells. We also examined type I procollagen (collagen I) and 
collagen IV expression in the various hBCC types. Collagen I 
expression was higher in BT-549 cells, and collagen IV expression 
was higher in MCF-10A and MDA-MB-157 cells, than in the other 
hBCCs (Figure 2-1B and D). 
LOXL4 knockdown promotes migration 
Fluorescence microscopy confirmed that the lentiviral vector facilitated 
doxycycline-dependent inducible RFP expression (Figure 2-2A), and 
flow cytometry revealed that the efficiency of lentivirus-mediated RFP 
gene transfer was over 97% (Figure 2-2B). Real-time RT-PCR 
revealed that lentiviral transduction of LOXL4 shRNA decreased 
LOXL4 mRNA levels (0.32 ± 0.05-fold) compared to the control 
(Figure 2C, P = 0.002). LOXL3 and LOXL4 are identical except for 
three amino acids; due to this similarity, LOXL3 mRNA levels also 
decreased 0.67 ± 0.08-fold in LOXL4-knockdown cells compared to 
the control (Figure 2C, P = 0.038). Interestingly, LOXL1 mRNA levels 
increased 2.87 ± 0.09-fold in LOXL4-knockdown cells compared to 
the control (Figure 2-2C, P = 0.0002). Consistent with the real-time 
RT-PCR results, Western blot analysis revealed that LOXL3 (0.61 ± 




protein levels were significantly decreased in LOXL4-knockdown cells 
compared to the control cells (Figure 2-2D). However, despite the 
increase observed in LOXL1 mRNA levels, LOXL4 knockdown did not 
change LOXL1 protein levels (Figure 2-2D). After the LOXL1 
precursor protein is synthesized, it undergoes post-translational 
processing by bone morphogenetic protein 1 [60, 61]; this may explain 
the inconsistency observed in LOXL4-knockdown-induced changes in 
LOXL1 mRNA and protein levels. 
The growth rates and colony forming capacity observed in 
LOXL4-knockdown MDA-MB-231 cells were similar to those of 
control MDA-MB-231 cells (Figure 2-2E and F). The migratory 
ability of LOXL4-knockdown cells increased 1.82 ± 0.24-fold in the 
trans-well migration assay (Figure 2-2G, P < 0.001). The invasive 
ability of LOXL4-knockdown cells also increased by 1.80 ± 0.46-fold 
in the Matrigel™ matrix-coated trans-well assay (Figure 2-2H, P = 
0.0001) and 1.78 ± 0.23-fold in the type I rat tail collagen-coated 
trans-well assay (Figure 2-2I, P < 0.001) compared to control cells. 
Cell characterization assays after LOXL4 knockdown were also 
conducted using MCF-7 (luminal subtype) and BT-549 (TN subtype) 
breast cancercells. LOXL4-knockdown and control MCF-7 cells had 




LOXL4-knockdown BT-549 on days 3 and 5 after cell seeding 
compared to control BT-549 cells (P < 0.001, Figure 2-4C). The 
colony forming capacities of LOXL4-knockdown MCF-7 and BT-549 
cells were similar to those of the respective control cells (Figure 2-3D 
and 2-4D). Migratory capacity did not differ between LOXL4-
knockdown and control MCF-7 cells (Figure 2-3E-G), but migratory 
and invasive abilities increased in LOXL4-knockdown BT-549 in the 
trans-well migration (1.31 ± 0.07-fold, P = 0.002) and the Matrigel™ 
matrix (1.87 ± 0.34-fold, P = 0.001), and collagen (1.85 ± 0.20-fold, 
P < 0.001) trans-well invasion assays compared to control BT-549 
cells (Figure 2-4E-G). 
LOXL4 knockdown promotes primary tumor growth and lung metastatic 
tumor formation 
We next investigated whether LOXL4 knockdown increased primary 
tumor growth and metastatic tumor formation in vivo. In an orthotopic 
xenograft model (n = 4 and 5 for the control and LOXL4-knockdown 
groups, respectively), LOXL4 knockdown increased tumor volumes in 
the 5th and 6th weeks after cancer cell injection compared to the 
control (Figure 2-5A, P = 0.008 and P = 0.040, 5th and 6th weeks, 
respectively). Bioluminescence images (BLI) and associated total flux 




mice were sacrificed. As expected, in vivo BLI signals were stronger in 
LOXL4-knockdown tumor sites (6.13x107 p/s/cm2/sr) than in control 
tumor sites (468.54x107 p/s/cm2/sr) (Figure 2-5B-C, P = 0.035). 
The gross appearance and ex vivo RFP fluorescence images showed 
bigger primary tumors from in LOXL4-knockdown mice than those 
from the control mice (Figure 2-5D). In the lung metastasis model, 
BLI signals indicated that the lung nodule formation ability of LOXL4-
knockdown cells (15.05x105 p/s/cm2/sr) was increased compared with 
that of control cells (108.77x105 p/s/cm2/sr) (P = 0.014, Figure 2-
5E-F). Images of the gross appearance of the lungs and of RFP 
fluorescence detection also clearly confirmed that LOXL4-knockdown 
increased numbers of lung tumor nodules compared to the control 
(Figure 2-5G). 
LOXL4 knockdown increases collagen I and IV, PLOD1, PLOD2, P4HA1, 
and P4HA2 expression in xenograft tumor tissues 
To investigate whether LOXL4 knockdown altered the structure of the 
ECM in tumor tissues, Picrosirius red and Masson’s trichrome staining 
were conducted. Strongly stained regions were observed within both 
primary tumors and lung nodules (Figure 2-6A-B). Histological 
analysis of primary tumors confirmed that LOXL4 expression was 




procollagen (Collagen I) and IV immunohistochemical (IHC) staining 
intensities were stronger in LOXL4 knockdown tumors than in control 
tumors (Figure 2-6D). LOXL4 knockdown also increased PLOD1-2 
and P4HA1-2 levels compared to controls (Figure 2-6E). Consistent 
with the IHC results, western blots revealed a trend towards decreased 
LOXL4 protein expression in LOXL4-knockdown tumors, although this 
difference was not statistically significant (Figure 2-6F-G). Type I 
procollagen (collagen I) and IV expression levels increased 3.30 ± 
1.40-fold (P = 0.01) and 4.19 ± 0.46-fold (P = 0.047), respectively, 
in LOXL4-knockdown tumors (Figure 4F-G). PLOD1 (2.31 ± 1.13-
fold, P = 0.002), PLOD2 (3.21 ± 0.10-fold, P < 0.001), and P4HA2 
(2.74 ± 0.29-fold, P = 0.048) expression also increased in LOXL4-
knockdown tumors compared to control tumors (Figure 2-6H-I). In 
addition, PLOD1 (1.29 ± 0.06-fold, P = 0.047) and PLOD2 (1.49 ± 
0.18-fold, P = 0.013) expression also increased in LOXL4-
knockdown MDA-MB-231 cells relative to control cells (Figure 2-7). 
IHC staining of collagen I and IV, PLOD1-2, and P4HA1-2 in lung 
metastatic tissues revealed that LOXL4 expression was suppressed in 
LOXL4-knockdown lung tumors (Figure 2-6J). Collagen I and IV 




control tumors (Figure 2-6K); PLOD1 and P4HA1-2 staining were 
also strong in LOXL4-knockdown lung tumors (Figure 2-6L-M). 
LOXL4 knockdown promotes thickening of collagen fibers 
We then used SHG imaging to examine whether LOXL4 knockdown 
altered collagen fiber structure and organization. Collagen fiber 
quantification was conducted using CT-FIRE, an open-source 
software package that was developed to automatically quantify 
individual collagen fibers in SHG images 
(http://loci.wisc.edu/software/ctfire) [62]. Fiber lengths and widths 
were calculated as pixel values. Straightness was calculated by dividing 
the distance between each fiber’s end points by the fiber path; the 
scale for this metric was 0-1, with 1 indicating a straight line. 
Although collagen fiber length and straightness did not differ between 
control and LOXL4-knockdown tissues, collagen fiber width was 
elevated in LOXL4-knockdown tumors compared to control tumors 
(Figure 2-8A-B, P = 0.041). 
Low LOXL4 and high collagen expression are associated with poor 
overall survival 
The BreastMark website was used to explore the association between 
LOXL4 and collagen I and IV expression and OS in breast cancer 




including 169 events from BreastMark, and the samples were 
separated into high and low LOXL4 expression groups. Kaplan-Meier 
plots revealed that OS was significantly shorter in the low LOXL4 level 
group (Figure 2-9A, P = 0.004, HR = 0.6395). Interestingly, OS was 
poorest in breast cancer patients with both low LOXL4 levels and high 
collagen I or IV expression (Figure 2-9B-C, P = 0.037, HR = 0.6718 
and P = 0.037, HR = 0.6619, respectively). We also analyzed OS in a 
set of 101 patients that included 36 who were diagnosed with TNBC 
using the PAM50 assay. Low LOXL4 expression was also associated 
with poor OS in these patients (Figure 2-9D, P = 0.009, HR = 0.427). 
While the trend towards an association between the combination of low 
LOXL4 and high collagen I expression and poorer OS did not reach 
significance (Figure 2-9E, P = 0.061, HR=0.4621), the low LOXL4 
and high collagen IV expression combination was significantly 
associated with poorer OS in TNBC patients (Figure 2-9F, P = 0.008, 









In the present study, we demonstrated that knockdown of LOXL4 
expression promoted primary tumor growth and lung metastasis in 
MDA-MB-231 cell xenograft models of breast cancer. These 
increases in tumor growth and metastasis were accompanied by 
alterations in the synthesis, deposition, structure of collagen, and 
specifically by an increase in bundle thickness. Furthermore, we found 
that low LOXL4 expression was associated with poorer overall survival 
in breast cancer patients. To the best of our knowledge, this is the first 
report to demonstrate a link between low LOXL4 expression and 
increased progression in TNBC. 
First, we evaluated the expression of the LOX family members, as 
well as collagen I and IV, in a diverse set of breast cancer cell lines. 
LOXL4 expression was higher in MDA-MB-231 cells, which are 
aggressive TNBC cells, than in cells belonging to the luminal and HER2 
subtypes. We then examined the effects of shRNA-mediated LOXL4 
knockdown in MDA-MB-231 cells; knockdown of LOXL4 increased 
the migratory and invasive abilities of these cells. While Kirschmann et 
al. reported that LOX and LOXL2 expression were most strongly 
associated with invasive potential in both highly invasive and metastatic 
breast cancer cell lines [63], our results indicate that LOXL4 also 




findings are inconsistent with a previous report that high LOXL4 mRNA 
levels may promote the transition from the solid to the effusion state in 
breast carcinomas [64]. We also found that LOXL4 expression differed 
among the hBCCs based on the breast cancer subtype to which they 
belonged. It is therefore likely that the role of LOXL4 may depend on 
heterogenous traits that vary in different types of breast cancer. 
Additional studies are needed to investigate the different roles of 
LOXL4 in breast cancer subtypes, particularly in TNBC. 
Although recent studies have examined the role of LOXL4 in breast 
cancer, the explanation for the seemingly contradictory results 
obtained in cell lines and in xenograft models remains unclear. In our 
orthotopic primary tumor and lung metastasis models, we showed that 
LOXL4 knockdown increased primary tumor growth and metastasis in 
MDA-MB-231 cells. The authors of the one other study using 
LOXL4-knockdown MDA-MB-231 cells concluded that LOXL4 
knockdown did not affect primary MDA-MB-231 cell tumor growth, 
but decreased spontaneous metastasis of MDA-MB-231 cells to the 
lungs in SCID and non-obese diabetic-SCID mice. The recruitment of 
CD11b-positive bone marrow-derived cells to sites of metastasis in 
the lungs was thought to underlie this effect [55]. These results, which 




different lung metastasis models, as well as differences in the tumor 
microenvironments of the host mice. 
In this study, LOXL4 knockdown increased collagen I and IV 
accumulation in both primary and lung tumor tissues in the xenograft 
models. PLOD1-2 and P4HA1-2, enzymes that are critical for 
collagen synthesis, may be predictive biomarkers for human cancer 
progression and metastasis [44-46]. Intriguingly, we found that 
PLOD1-2 and P4HA1-2 expression were elevated in LOXL4-
knockdown primary and lung tumors. The increases in collagen I and IV 
expression in LOXL4-knockdown tumors might be associated with this 
increase in PLOD1-2 and P4HA1-2 expression, which is likely 
regulated by LOXL4-mediated intracellular signaling. In addition, 
NADPH oxidase (NOX) family genes, which also have pro-fibrotic 
effects, regulate the ECM and collagen synthesis in response to other 
signaling mechanisms, such as TGF-β and reactive oxygen species 
[65]. Although we did not investigate the effects of interactions 
between LOXL4 and NOX on collagen production in this study, NOX 
might also contribute to the LOXL4 knockdown-induced increase in 
collagen synthesis in breast cancer cells.  
Straightened and aligned collagen fiber bundles were correlated 
with poor disease-specific and disease-free survival in an evaluation 




(TACS-3) and long-term survival rates in breast cancer patients [66]. 
Here, we found that collagen bundles were thicker in LOXL4-
knockdown tumors than in control tumors, but no changes in the 
linearization or the length of the collagen fibers were found. This 
indicates that increased collagen bundle thickness in LOXL4-
knockdown tumors might have accelerated primary tumor growth and 
lung metastasis in the MDA-MB-231 xenograft model.  
Although extensive preclinical research has advanced our 
understanding of the mechanisms by which the LOX family increases 
fibrosis in the ECM, few studies have linked LOXL4 expression with 
clinical outcomes in breast cancer patients. A recent study found that 
LOXL4 was downregulated in hepatocellular carcinoma, and this 
downregulation was closely correlated with worse clinical outcomes 
[67]. Similarly, based on an OS analysis using data from the public 
database at the BreastMark website, we found that low LOXL4 
expression was also associated with poor OS in breast cancer patients, 
suggesting that LOXL4 expression could be a useful prognostic marker 
in breast cancer. Moreover, this relationship between low LOXL4 
expression and poor clinical outcome was strongest in patients with 
TNBC. Finally, OS was worst in TNBC patients with both low LOXL4 




 In this study, we demonstrated that low LOXL4 expression is 
associated with increases in the progression of aggressive TNBC. 
However, because LOXL4 expression is also associated with other risk 
factors, particularly collagen levels and structural changes in the ECM, 
future studies with larger patient populations are needed to determine 
whether low LOXL4 levels can serve as an independent prognostic 





Figure 1-1. Comparison of gene expression and migration in miR-
200b/200a/429 or miR-141/200c-transduced MCF-7 and MDA-MB-
231 cells. (A) Fluorescence images of green fluorescent protein in 




encoding both GFP and miR-200 family members. Scale bar, 50 μm (B) 
RT-PCR analysis of genes related to epithelial-mesenchymal 
transition (E-cadherin, fibronectin, vimentin, ZEB1, ZEB2, and snail). 
(C) Images of the crystal violet-stained cells that migrated 
horizontally in the trans-well migration assay. (D) Images of the 
laterally migrated cells as determined using a wound-healing assay. (E) 
Quantitative analysis of the migratory ability of MCF-7 and MDA-
MB-231 cells assessed using trans-well migration assay. (F) 
Quantitative analysis of the migratory ability of MCF-7 and MDA-
MB-231 cells assessed using wound-healing assays. All experiments 
were performed at least in triplicate, and the values are the mean 
values ± standard deviation. *P < 0.05.  
 
 
Figure 1-2. Flow cytometric analysis of GFP in miR-200b/200a/429 or 




cytometry analysis of the percentage of GFP-positive cells among the 




Figure 1-3. Proliferation, migration, and invasion of miR-
200b/200a/429- or miR-141/200c-transduced MDA-MB-231 cells. 
(A) Fluorescence images of green fluorescent protein in MCF-7 and 
MDA-MB-231 cells that were transduced using lentivirus encoding 
both GFP and miR-200 family members. Scale bar; 50 μm (B) 
Quantitative real-time RT-PCR of microRNAs (miR-200a, miR-200b, 
and miR-200c). (C) MTT assay for analysis of cell proliferation. (D) 
Trans-well migration assay for the analysis of cell migration. (E) 




experiments were performed at least in triplicate, and the values are 
the mean values ± standard deviation. *P < 0.05, **P < 0.001. 
 
Figure 1-4. Migration in miR-141/200c-transduced MDA-MB-231 
cells. Quantitative analysis of the migratory ability in of MDA-MB-231 
and miR-141/200c-transduced MDA-MB-231 cells was performed in 
trans-well migration assay with 10% FBS in the lower chamber. All 
experiments were performed at least in triplicate, and the values are 





Figure 1-5. Migration in miR-141/200c-transduced HCC-38 and 
Hs578T cells treated with an anti-VEGF-A-neutralizing antibody. (A, 
D) Migration in miR-141/200c-transduced HCC-38 and Hs578T cells. 
Images of the crystal violet-stained cells that migrated horizontally in 
the trans-well migration assay (upper). The absorbance values of 
extracted crystal violet in migrated cells (lower). (B, E) Measurement 
of the secreted levels of cytokines and growth factors (IL-2, IL-4, 
IL-5, IL-10, IL-12, IL-13, GM-CSF, IFN-γ, TNF-α, and VEGF-A). 
(C, F) Trans-well migration of anti-VEGF-A-neutralizing antibody-






Figure 1-6. microRNA expression levels of miR-200 cluster 
transduced MCF-7, MDA-MB-231, HCC-38, and Hs578T cells. 
Quantitative real-time RT-PCR of microRNAs (miR-200a, miR-200b, 
and miR-200c). (A, B, C) microRNAs in MCF-7 cells. (D, E, F) 
microRNAs in MDA-MB-231. (G) microRNAs in HCC-38. (H) 






Figure 1-7. Signaling pathway associated with enhanced migration in 
miR-200b/200a/429 or miR-141/200c-transduced MDA-MB-231 
cells. (A, B) Western blotting analysis of the levels of phosphorylated 
FAK, AKT, ERK, and integrin-αV expression. Densitometric 
quantifications of FAK, AKT, and ERK phosphorylation in the miR-200 
family-transduced cells relative to control cells. β−actin was used as 
an internal reference. (C) Immunofluorescence analysis of 
phosphorylated FAK and integrin-αV. (D) Trans-well migration assay 
of FAK (PF573228) and PI3K/AKT (LY294002)-inhibitor-treated 




values are the mean values ± standard deviation.. *P < 0.05, **P < 
0.001, Scale bar, 10 μm. 
 
Figure 1-8. VEGF-A expression and signaling pathways associated 
with enhanced migration in miR-141/200c-transduced HCC-38 cells. 
(A) Representative image of western blotting analysis of VEGF-A 
levels. β−actin was used as an internal reference. (B) Densitometric 
quantification of VEGF-A in the miR-141/200c-transduced cells 
relative to the control cells. (C) Western blotting analysis of the levels 
of phosphorylated FAK, AKT, ERK, and integrin-αV expression. 
β−actin was used as an internal reference. (D) Densitometric 




141/200c-transduced cells relative to the control cells. (E) 
Immunofluorescence analysis of phosphorylated FAK and integrin-αV. 
*P < 0.05. Scale bar, 10 μm. 
 
Figure 1-9. Migration and invasion in miR-200b/200a/429 or miR-
141/200c-transduced MDA-MB-231 cells treated with an anti-
VEGF-A-neutralizing antibody. (A) Measurement of the secreted 
levels of cytokines and growth factors (IL-2, IL-4, IL-5, IL-10, IL-
12, IL-13, GM-CSF, IFN-γ, TNF-α, and VEGF-A). (B) Western 




and (D) invasion assay of anti-VEGF-A-neutralizing antibody-
treated cells. (E, F) Representative image of western blotting of 
phosphorylated AKT, FAK, and ERK and total AKT, FAK and ERK in 
cells treated with anti-VEGF-A-neutralizing antibodies for 30 min 
and 48 h. All experiments were performed at least in triplicate, and the 
values are the mean values ± standard deviation. N.D: not detectable. 
*P < 0.05, **P < 0.001.  
 
Figure 1-10. Migration and signaling pathways in VEGF-A-stimulated 
MDA-MB-231 cells. (A) Images of the crystal violet-stained cells 




absorbance values of extracted crystal violet in migrated cells. (C) 
Representative image of western blotting of phosphorylated AKT, FAK 
and ERK and total AKT, FAK and ERK in MDA-MB-231 cells treated 
with VEGF-A. (D) Densitometric quantifications of phosphorylation 
levels of FAK, AKT, and ERK in the VEGF-A-treated cells relative to 
the untreated cells. β−actin was used as an internal reference. All 
experiments were performed at least in triplicate, and the values are 





Figure 1-11. Migration and signaling pathways in VEGF-A-stimulated 
HCC-38 cells. (A) Migration in VEGF-A-stimulated HCC-38 cells. 
Images of the crystal violet-stained cells that migrated horizontally in 
the trans-well migration assay. (B) The absorbance values of 
extracted crystal violet in migrated cells (lower). (C) Representative 
image of western blotting of phosphorylated AKT, FAK and ERK and 
total AKT, FAK and ERK in HCC-38 cells treated with VEGF-A. (D) 
Densitometric quantification of VEGF-A in the miR-141/200c-
transduced cells relative to the control cells. β−actin was used as an 





Figure 2-1. LOX family member, collagen I, and collagen IV expression 
in various breast cancer cells. (A and B) Western blotting analysis of 
LOX family (LOX and LOXL1-4), collagen I, and collagen IV protein 
expression in normal breast epithelial cells (MCF-10A) and luminal 
(MCF-7, BT-474), HER2 (MDA-MB-453, SK-BR3, and HCC1954), 
and TN (BT-549, MDA-MB-157, MDA-MB-231, MDA-MB-468, 
and HCC1937) breast cancer cell lines. (C and D) LOX family, type I 
procollagen (collagen I), and collagen IV protein expression in breast 





Figure 2-2. Establishment and characterization of the LOXL4 
knockdown MDA-MB-231 cells. (A) Fluorescence images of 
doxycycline-inducible red fluorescent protein expression in MDA-
MB-231 cells transduced with lentivirus encoding both RFP and either 
the non-silencing control vector or shLOXL4. Scale bar: 50 μm. (B) 
Flow cytometric analysis of the percentage of RFP-positive control or 




RT-PCR of LOX and LOXL1-4. (D) Western blotting analysis of LOX 
family member protein expression. (E) MTT assay for analysis of cell 
proliferation. (F) Single cell colony formation assay. Scale bar: 100 μm. 
(G) Trans-well migration assay for the analysis of cell migratory 
capacity. (H and I) Trans-well invasion assays for the analysis of cell 
invasion capacity. All experiments were performed at least in triplicate; 
means ± standard deviation of all experiments are shown. *P < 0.05. 








Figure 2-3.  Establishment and characterization of LOXL4 knockdown 
MCF-7 cells. (A) Flow cytometric analysis of the percentage of RFP-
positive control and LOXL4-knockdown MCF-7 cells. (B) Quantitative 
real-time RT-PCR of LOXL4. (C) MTT assay for analysis of cell 
proliferation. (D) Single cell colony formation assay. (E) Trans-well 
migration assay for the analysis of cell migratory capacity. (F and G) 
Trans-well invasion assays for the analysis of cell invasion capacity. 




deviation of all experiments are shown. *P < 0.05. **P < 0.001. Scale 
bar: 200 μm. 
 
Figure 2-4. Establishment and characterization of LOXL4 knockdown 
BT-549 cells. (A) Flow cytometric analysis of the percentage of RFP-
positive control and LOXL4-knockdown BT-549 cells. (B). 
Quantitative real-time RT-PCR of LOXL4. C. MTT assay for analysis 




Trans-well migration assay for the analysis of cell migratory capacity. 
(F and G) Trans-well invasion assays for the analysis of cell invasion 
capacity. All the experiments were performed at least in triplicate; 
means ± standard deviation of all experiments are shown. *P < 0.05. 
**P < 0.001. Scale bar: 100 μm. 
 
Figure 2-5. LOXL4 knockdown increased primary tumor growth and 
lung metastasis of MDA-MB-231 breast cancer cells. (A) Changes in 
tumor volume after injection of MDA-MB-231 cells transduced with 
control or shLOXL4. (B) Representative bioluminescence images of the 
tumors obtained with the IVIS system on day 41 after cancer cell 
injection. (C) Total flux values (p/s/cm2/sr) measured in 
bioluminescence images (day 41) of the primary tumors. Control and 
shLOXL4, n = 4 and 5, respectively. (D) Images of the final lung gross 




Representative bioluminescence images of tumor burdens in lungs 
obtained on day 56 after tail vein injections of cancer cells. n = 5. (F) 
Total flux (p/s/cm2/sr) measured in bioluminescence images of the 
metastatic lung burden (day 56). (G) Images of the final lung gross 
appearance, doxycycline-induced RFP in lung metastatic nodules, and 





Figure 2-6. LOXL4 knockdown increases collagen synthesis and 
deposition. (A) Images of H&E-, Picrosirius red-, and Masson’s 
trichrome-stained sections of primary tumors resulting from injection 
of control and LOXL4-knockdown cells. Scale bar: 400 μm. (B) Images 




sections after injection of control and LOXL4-knockdown cells. Scale 
bar: 400 μm. (C and D) Representative immunohistological (IHC) 
images of LOXL4, collagen I, and collagen IV staining in primary 
tumors. Scale bar: 100 μm. (E) Representative IHC images of PLOD1-
2 and P4HA1-2 staining in primary tumors. Scale bar: 100 μm. (F) 
Representative images of Western blots for LOXL4, type I procollagen 
(collagen I), and collagen IV. (G) Densitometric quantification of 
LOXL4, type I procollagen (collagen I), and collagen IV expression in 
tumors. (H) Western blotting analysis of PLOD1-2 and P4HA1-2 
expression in primary tumors. (I) Densitometric quantification of 
PLOD1-2 and P4HA1-2 expression in tumors. (J and K) 
Representative IHC images of LOXL4, collagen I, and collagen IV 
staining in the lungs. Scale bar: 100 μm. (L and M) Representative IHC 
images of PLOD1-2 and P4HA1-2 staining in the lungs. Scale bar: 200 






Figure 2-7. PLOD1, PLOD2, P4HA1, and P4HA2 expression in LOXL4 
knockdown MDA-MB-231 cells. (A) Western blotting analysis of 
PLOD1-2 and P4HA1-2 protein expression. (B) Densitometric 
quantification of PLOD1-2 and P4HA1-2 expression. 
 
Figure 2-8. Second harmonic generation (SHG) imaging of control and 
LOXL4-knockdown primary tumor tissues. (A) Representative SHG 




control and LOXL4-knockdown primary tumor tissues (right). (B) 
Quantification of collagen fiber lengths, straightness, and widths in 
control and LOXL4-knockdown primary tumor tissues. n = 5. *P < 
0.05. Scale bar: 100 μm. 
 
Figure 2-9. Kaplan-Meier plots of breast cancer patient survival based 
on LOXL4, collagen I, and collagen IV expression in the BreastMark 
dataset. (A) Low expression of LOXL4 was associated with a poor 
overall survival (OS) in total breast cancer. n = 584, number of events 
= 169, Hazard ratio (HR) = 0.6395 (0.4704-0.8694), score (log rank) 
test = 8.28, P = 0.004. (B) The combination of low LOXL4 and high 
collagen I expression was associated with poor OS in total breast 
cancer. n = 584, number of events = 169, HR = 0.6718 (0.4612-




of low LOXL4 and high collagen IV expression was associated with a 
poor OS in total breast cancer. n = 584, number of events = 169, HR = 
0.6619 (0.4483-0.9774), score (log rank) test = 15.36, P = 0.036. (D) 
Low expression of LOXL4 was associated with a poor OS in triple 
negative breast cancer (TNBC). n = 101, number of events = 36, HR 
= 0.427 (0.2207-0.8259), score (log rank) test = 6.78, P = 0.009. (E) 
The combination of low LOXL4 and high collagen I expression showed 
a borderline association with the OS in TNBC. n = 101, number of 
events = 36, HR=0.4621 (0.2018-1.058), score (log rank) test = 3.5, 
P = 0.061. (F) The combination of low LOXL4 and high collagen IV 
expression was associated with a poor OS in TNBC. n = 101, number 
of events = 36, HR = 0.3006 (0.1166-0.7749), score (log rank) test 
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서론: microRNA-200 (miR-200) family 는 E-Cadherin 의 
전사억제인자인 ZEB1 과 ZEB2 의 발현을 억제하여 상피간엽이행 
(Epithelial to Mesenchymal Transition)에 중요한 조절 인자로 알려져 
있으나 유방암세포의 이동성과 침윤성 관련하여 miR-200 family 의 
역할은 논란이 많다. 또한 lysyl oxidase-like 4 (LOXL4)는 lysyl 
oxidase (LOX) family 중 하나로 세포외 기질 변형과 세포의 증식 및 
생존과 관련된 신호전달기전에 관여하는 것으로 알려져 있으나 유방암 
진행과 전이에서 LOXL4 의 역할은 명확히 밝혀져 있지 않다. 따라서 본 
연구에서는 miR-200 이 어떠한 기전에 의해 유방암 아형 중 예후가 
가장 나쁜 삼중음성 유방암세포의 이동과 침윤 능력을 변화시키는지 
규명하고자 한다. 또한 LOXL4 가 어떠한 기전에 의해 삼중음성 유방암 
형성과 전이를 조절하는가를 규명하고 유방암 환자의 예후인자로서의 
의의를 분석하고자 한다.  
실험방법: 렌티바이러스 시스템을 이용해 miR-200b/200a/429 
cluster 혹은 miR-141/200c cluster 와 녹색형광단백질 (GFP)을 
안정적으로 발현하는 삼중음성 유방암세포인 MDA-MB-321 세포주와 
LOXL4 short hairpin RNA (shLOXL4), 적색형광단백질 (RFP), 
루시퍼라제 (firefly luciferase)와 녹색형광단백질을 발현하는 MDA-




(real-time RT-PCR)이나 역전사 중합효소 연쇄반응 (RT-PCR)으로 
분석하였다. 이동과 침윤 능력은 트랜스웰 (trans-well)이나 운드힐링 
(wound-healing) 실험법으로 확인하였다. 세포에서 분비된 
사이토카인과 성장 인자들은 바이오플랙스 200 멀티플랙스 (Bio-Plex 
200 multiplex) 어레이 시스템으로 정량화하였다. 세포 내 신호 전달을 
분석하기 위해 웨스턴 분석과 면역형광염색을 수행했다. 6 주령 
면역결핍마우스 (BALB/c nude)의 유방의 지방패드나 꼬리 정맥에 
유방암 세포를 주입하여 일차암과 폐전이 종양동물모델을 만들었다. 
일차암 부피는 디지털캘리퍼스로 측정하였고 생체발광영상장비 
(IVIS)와 생체광학장비 (Maestro)를 이용하여 일차암과 폐전이암을 
분석하였다. 적출한 종양조직에서 H&E 염색, 특수염색 (Picrosirius red, 
Masson’s trichrome)과 면역염색을 수행하였다. 콜라겐 섬유의 길이, 
평면성과 두께를 정량화 하기 위해 제 2 고조파 발생 영상 기법 
(Second-harmonic generation imaging, SHG)을 사용하였다. 퍼블릭 
데이터베이스 (BreastMark)를 사용하여 LOXL4, 콜라겐 1, 콜라겐 4 
유전자에 대한 유방암환자의 생존율을 분석, 예후인자로서의 의의를 
확인하였다. 
결과: miR-200b/200a/429 혹은 miR-141/200c 과발현은 MDA-
MB-231 세포의 성장을 억제시켰고 이동, 침윤 능력을 증가시켰으며 
세포 내 신호전달인자인 FAK 와 AKT 의 인산화를 증가시켰다. 




141/200c 의 과발현에 의해 증가된 이동과 침윤능력을 억제하였다. 
그리고 miR-200b/200a/429 과발현과 비교할 때, miR-141/200c 
과발현은 MDA-MB-231 세포에서 VEGF-A 분비와 integrin-αV 
발현을 현저하게 증가시켰다. VEGF-A 중화항체의 처리는 miR-
200b/200a/429 혹은 miR-141/200c 과발현에 의해 증가된 MDA-
MB-231 세포의 이동, 침윤 능력을 억제하였고 FAK 와 AKT 인산화를 
감소시켰다. LOXL4 발현의 감소는 마우스 종양모델에서 MDA-MB-
231 세포의 일차암 형성과 폐전이 능력을 증가시켰다. LOXL4 발현을 
감소시킨 종양조직에서 PLOD1, PLOD2, P4HA1, P4HA2 뿐만아니라 
콜라겐 1 과 콜라겐 4 의 발현이 현저하게 증가되었다. 또한 대조군에 
비해 LOXL4 발현이 감소된 종양 조직 내 콜라겐 다발이 더 두꺼워지는 
것을 관찰했다. 유방암 환자 (n=584)의 생존율 분석 결과, LOXL4 의 
발현이 낮은 군에서는 생존율이 낮았으며 콜라겐 1 과 콜라겐 4 의 
발현이 높고 LOXL4 발현이 낮은 군에서는 생존기간이 감소하였다. 특히 
삼중음성 유방암 환자 (n=101)에서 LOXL4 발현이 낮고 콜라겐 1 과 
콜라겐 4 의 발현이 높은 경우 생존율과 생존기간이 유의하게 
감소하였다. 
결론: 삼중음성 유방암세포에서 miR-141/200c 과발현은 VEGF-A 의 
분비를 통해 세포 내 신호전달인자인 FAK 와 AKT 를 활성화 시켜 
세포의 이동과 침윤능력을 촉진시켰다. 또한 LOXL4 의 발현억제는 




일차암 성장과 폐전이를 증대시켰다.  LOXL4 는 삼중음성 유방암 
환자의 생존을 예측하는 예후인자로 역할을 할 수 있을 것으로 기대된다. 
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